Our data show that proposed approach utilizing complex gene- and chemotherapy (simultaneous delivery of TAX and siRNAs targeted to the pool of EGFR-TKs) effectively killed all types of human NSCLC cells (with and without mutations of EGFR-TKs). This evidence concerns the gene CDC42 and non-small cell lung carcinoma.